Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.67 |
| ▸ | RAB9A | P51151 | 8/20 | 0.67 |
| ▸ | NPC1 | O15118 | 5/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | AR | P10275 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2555926 | 0.86 | SMN1; SMN2 (0.71) | SMN1; SMN2RAB9ANPC1MAPK1MAPT | |
| SCHEMBL3813999 | 0.86 | SMN1; SMN2 (0.68) | SMN1; SMN2RAB9ANPC1MAPK1MAPT | |
| SCHEMBL2554297 | 0.83 | SMN1; SMN2 (0.78) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL3816958 | 0.83 | RAB9A (0.73) | SMN1; SMN2RAB9ANPC1MAPK1MAPT | |
| SCHEMBL2043877 | 0.82 | FFAR2 (0.64) | SMN1; SMN2RAB9ANPC1MAPK1MAPT | |
| SCHEMBL29157423 | 0.80 | SMN1; SMN2 (0.70) | SMN1; SMN2RAB9ANPC1MAPK1MAPT | |
| SCHEMBL3006940 | 0.80 | SMN1; SMN2 (0.58) | SMN1; SMN2RAB9ANPC1MAPK1MAPT | |
| SCHEMBL3017336 | 0.78 | SMN1; SMN2 (0.56) | SMN1; SMN2RAB9ANPC1MAPK1MAPT | |
| SCHEMBL2224767 | 0.77 | SMN1; SMN2 (0.49) | SMN1; SMN2RAB9ANPC1MAPTMEN1 | |
| SCHEMBL12937251 | 0.76 | PTPN1 (0.48) | SMN1; SMN2RAB9ANPC1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296974-A2 | 2-CYANOPYRROLIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2003-04-02 | — | — | EP | disclosed |
| US-20020193390-A1 | Pharmaceutical compositions containing an N-(substituted glycyl)-2- cyanopyrrolidine and at least one other antidiabetic agent and their use in inhibiting dipeptidyl peptidase-IV | VILLHAUER EDWIN BERNARD (US) | 2002-12-19 | — | — | US | disclosed |
| US-6432969-B1 | NON-INSULIN DEPENDENT DIABETES, OBESITY, ARTHRITIS, AND OSTEOPOROSIS TREATMENT | NOVARTIS AG (CH) | 2002-08-13 | — | — | US | disclosed |
| WO-2001096295-A2 | 2-CYANOPYRROLIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193390-A1 | Pharmaceutical compositions containing an N-(substituted glycyl)-2- cyanopyrrolidine and at least one other antidiabetic agent and their use in inhibiting dipeptidyl peptidase-IV | DPP4, DPP9, DPP7 | SMN1; SMN2 2692/4885RAB9A 3466/4885NPC1 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.